



WELCOME TO THE E-CONGRESS 2020

Secukinumab Improves Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations with Inadequate Response to NSAIDs: **Week 52 Results** from the MAXIMISE Trial

X Baraliakos¹, L Gossec², E Pournara³, S Jeka⁴, R Blanco⁵, S D'Angelo⁶, G Schett⁷, B Schulz³, M Rissler³, K Nagar⁸, C Perella³ and L C Coates⁹

¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany; ²Sorbonne Universités, Paris, France; ³Novartis Pharma AG, Basel, Switzerland; ⁴2nd University Hospital, CM UMK, Bydgoszcz, Poland; ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain; ⁶Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy; ⁷University of Erlangen-Nuremberg, Erlangen, Germany; ⁸Novartis Healthcare Pvt. Ltd., Hyderabad, India; ⁹University of Oxford, Oxford, United Kingdom